Mostrar el registro sencillo del ítem
dc.contributor.author | López Galindo, Mónica Paula | |
dc.contributor.author | Bagán Sebastián, José Vicente | |
dc.date.accessioned | 2015-11-20T08:26:26Z | |
dc.date.available | 2015-11-20T08:26:26Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | López-Galindo, M., & Bagán, J. V. (2015). Apixaban and oral implications. Journal of clinical and experimental dentistry, 7(4), e528. | spa |
dc.identifier.issn | 19895488 | |
dc.identifier.uri | http://hdl.handle.net/11268/4582 | |
dc.description.abstract | Thrombotic disorders remain a leading cause of death in the Western world, and in this regard a number of anticoagulation treatment have been used, including heparins, fondaparinux, vitamin K antagonists (warfarin, acenocoumarol), and new oral anticoagulants such as apixaban. For years there has been great controversy regarding the use of anticoagulants in planning dental treatments that imply bleeding. The main concerns about using new oral anticoagulants in invasive dental procedures are bleeding due to the lack of an antidote, and the thrombotic risk of the disease for which anticoagulation was indicated in the first place. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.subject.other | Apixaban | spa |
dc.subject.other | Dental treatment | spa |
dc.subject.other | Dental implications | spa |
dc.title | Apixaban and oral implications | spa |
dc.type | article | spa |
dc.description.impact | 0.332 SJR (2015) Q3, 69/120 Dentistry (miscellaneous) | spa |
dc.identifier.doi | 10.4317/jced.52470 | |
dc.rights.accessRights | closedAccess | spa |
dc.subject.uem | Medicamentos | spa |
dc.subject.uem | Odontología | spa |
dc.subject.unesco | Medicamento | spa |
dc.subject.unesco | Odontología | spa |
dc.description.filiation | UEV | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |